Genetic dissection of atypical antipsychotic-induced weight gain: Novel preliminary data on the pharmacogenetic puzzle

Journal of Clinical Psychiatry

Volumn 62, Issue SUPPL. 23, 2001, Pages 45-66

  Basile, V S ^a   Masellis, M ^a   McIntyre, R S ^a   Meltzer, H Y ^a   Lieberman, J A ^a   Kennedy, J L ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; CLOZAPINE; CYTOCHROME P450 1A2; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; NEUROLEPTIC AGENT; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL PRACTICE; DISEASE PREDISPOSITION; EXTRAPYRAMIDAL SYMPTOM; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HEREDITY; HUMAN; OBESITY; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEDATION; TREATMENT PLANNING; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CYTOCHROME P-450 CYP1A2; ENERGY METABOLISM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HOMEOSTASIS; HUMANS; HYPOTHALAMUS; MALE; OBESITY; PHARMACOGENETICS; RECEPTORS, ADRENERGIC; RECEPTORS, HISTAMINE; SCHIZOPHRENIA; SEROTONIN; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT GAIN;

EID: 0034785813     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (193)

1. Antipsychotic-induced weight gain: A comprehensive research synthesis
2. The distribution of body mass index among individuals with and without schizophrenia
3. NHLBI obesity education initiative expert panel on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report
4. Mortality and optimal body mass index in a sample of the US population
5. The spread of the obesity epidemic in the United States, 1991-1998
6. Weight gain from novel antipsychotic drugs: Need for action
7. Application of pharmacogenetics to schizophrenia: Emerging insights from studies of clozapine response and tardive dyskinesia
8. Why pharmacogenomics? Why now?
9. The business of pharmacogenomics
10. Inventing the pharmacogenomics business
11. Pharmacogenetics and pharmacogenomics: Why is this relevant to the clinical geneticist?
12. DNA microarrays in drug discovery and development
13. Pharmacogenetics of antipsychotic treatment: Lessons leamed from clozapine
14. Applications of pharmacogenetics in psychiatry: Personalisation of treatment
15. 3 receptor gene with tardive dyskinesia in schizophrenia
16. 3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients
17. 3 receptor and tardive dyskinesia in chronic schizophrenia
18. 3 receptor gene variants with neuroleptically induced akathisia in schizophrenic patients
19. 2C receptor
20. Neural network analysis of complex traits
21. Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia
22. Weight change and atypical antipsychotic treatment in patients with schizophrenia
23. Pharmacological actions of the atypical antipsychotic drug clozapine: A review
24. Radioreceptor binding profile of the atypical antipsychotic olanzapine
25. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
26. Clozapine-induced weight gain: Prevalence and clinical relevance
27. Clozapine and weight gain
28. Serum leptin levels increase rapidly after initiation of clozapine therapy
29. Role of serotonin in the action of atypical antipsychotic drugs
30. Evidence for a physiological regulation of food selection and nutrient intake in twins
31. The search for human obesity genes
32. Major gene effect on body mass index: The role of energy intake and energy expenditure
33. The body-mass index of twins who have been reared apart
34. The heritability of body mass index among an international sample of monozygotic twins reared apart
35. Recent advances in basic obesity research
36. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: Association with tardive dyskinesia in schizophrenia
37. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia
38. 3 receptor genes
39. Modeling gene-gene interactions in complex traits
40. Insulin and leptin: Dual adiposity signals to the brain for the regulation of food intake and body weight
41. Pathophysiological significance of the obese gene product, leptin, in ventromedial hypothalamus (VMH)-lesioned rats: Evidence for loss of its satiety effect in VMH-lesioned rats
42. Food intake and the regulation of body weight
43. Recombinant mouse OB protein: Evidence for a peripheral signal linking adiposity and central neural networks
44. Recombinant ob protein reduces feeding and body weight in the ob/ob mouse
45. Congenital leptin deficiency is associated with severe early-onset obesity in humans
46. Positional cloning of the mouse obese gene and its human homologue
47. Weight-reducing effects of the plasma protein encoded by the obese gene
48. Up-regulation of blood-brain barrier short-form leptin receptor gene products in rats fed a high fat diet
49. Leptin receptor signal transduction: OBRa and OBRb of fa type
50. Evidence that the diabetes gene encodes the leptin receptor: Identification of a mutation in the leptin receptor gene in db/db mice
51. Abnormal splicing of the leptin receptor in diabetic mice
52. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor
53. Body weight and leptin plasma levels during treatment with antipsychotic drugs
54. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses
55. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses
56. Insulin and leptin levels in patients with schizophrenia or related psychoses: A comparison between different anti-psychotic agents
57. The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects
58. Saturable transport of insulin from plasma into the central nervous system of dogs in vivo: A mechanism for regulated insulin delivery to the brain
59. Insulin and insulin-like growth factors in the CNS
60. Role of brain insulin receptor in control of body weight and reproduction
61. Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons
62. Effect of intracerebroventricular insulin infusion on diabetic hyperphagia and hypothalamic neuropeptide gene expression
63. Increased feeding in response to bilateral injection of insulin antibodies in the VMH
64. Chronic intrahypothalamic infusions of insulin or insulin antibodies alter body weight and food intake in the rat
65. Acute and chronic effects of insulin on leptin production in humans: Studies in vivo and in vitro
66. Leptin suppression of insulin secretion and gene expression in human pancreatic islets: Implications for the development of adipogenic diabetes mellitus
67. The effect of clozapine on glucose metabolism
68. Novel antipsychotics and new onset diabetes
69. Atypical neuroleptics and glucose regulation
70. Differential regulation of neuropeptide Y mRNA expression in the arcuate nucleus and locus coeruleus by stress and antidepressants
71. Increased neuropeptide Y concentrations in specific hypothalamic regions of streptozocin-induced diabetic rats
72. Effects of neuropeptides and leptin on nutrient partitioning: Dysregulations in obesity
73. Adrenalectomy reduces neuropeptide Y-induced insulin release and NPY receptor expression in the rat ventromedial hypothalamus
74. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
75. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice
76. Control of feeding and sexual behaviors by neuropeptide Y: Physiological implications
77. Neuropeptide Y in hypothalamic paraventricular nucleus: A center coordinating energy metabolism
78. Suppression of neuropeptide Y-elicited eating by adrenalectomy or hypophysectomy: Reversal with corticosterone
79. The how and Y of eating
80. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y
81. Chronic antipsychotic treatment selectively alters nerve growth factor and neuropeptide Y immunoreactivity and the distribution of choline acetyl transferase in rat brain regions
82. Effects of typical and atypical antipsychotics on neuropeptide Y in rat brain tissue and microdialysates from ventral striatum
83. Clozapine decreases neuropeptide Y-like immunoreactivity and neuropeptide Y mRNA levels in rat nucleus accumbens
84. Melanocortins and body weight: A tale of two receptors
85. A C-terminal fragment of agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo
86. Separate systems for serotonin and leptin in appetite control
87. Serotonin and appetite
88. Anxiety and depression: Discrete diagnostic entities?
89. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers
90. Dexfenfluramine: An updated review of its therapeutic use in the management of obesity
91. Serotonin and appetite regulation: Implications for the pharmacological treatment of obesity
92. The effects of peripheral serotonin2 receptor agonist on food intake of rats
93. Serotonin receptors in the human brain, 3: Autoradiographic mapping of serotonin-1 receptors
94. Serotonin receptors in the human brain, 4: Autoradiographic mapping of serotonin-2 receptors
95. 2C serotonin receptors
96. 2C receptor gene
97. Leptin increases serotonin turnover by inhibition of brain nitric oxide synthesis
98. 5-Hydroxytryptaminergic receptor agonists: Effects on neuropeptide Y potentiation of feeding and respiratory quotient
99. 2A receptor gene polymorphism is associated with food and alcohol intake in obese people
100. Body weight gain induced by antipsychotic drugs: Mechanisms and management
101. Natural structural variants of human serotonin receptors
102. HTR2C Cys23Ser polymorphism in relation to CSF monoamine metabolite concentrations and DSM-III-R psychiatric diagnoses
103. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients
104. 1A (HTR1A) receptor gene
105. 2A receptor influences amplitude and timing of intracellular calcium mobilization
106. Neuropharmacology of obesity: My receptors made me eat it
107. Hypothalamic neuronal histamine modulates adaptive behavior and thermogenesis in response to endogenous pyrogen
108. Zucker obese rats: Defect in brain histamine control of feeding
109. 1-histamine receptor agonist betahistine on drinking and eating behavior in pygmy goats
110. Involvement of the histaminergic system in leptin-induced suppression of food intake
111. Hypothalamic neuronal histamine as a target of leptin in feeding behavior
112. Mechanism of the central hyperglycemic action of histamine in mice
113. Novel antipsychotics: Comparison of weight gain liabilities
114. Cimetidine suspension as adjuvant to energy restricted diet in treating obesity
115. 2 receptor blockaders and weight control
116. Combination of diet, exercise and intermittent treatment of cimetidine on body weight and maintenance of weight loss: A 42 months follow-up study
117. H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients
118. Histamine H2 receptor gene variants: Lack of association with schizophrenia
119. Pharmacokinetics of clozapine and risperidone: A review of recent literature
120. Single- vs multiple dose pharmacokinetics of clozapine in psychiatric patients
121. 4 receptor gene
122. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test
123. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a therapeutic drug monitoring service
124. Very high cytochrome P4501A2 activity and nonresponse to clozapine
125. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine
126. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: Effect on the CYP1A2 inducibility in humans
127. The uncoupling protein UCP: A membraneous mitochondrial ion carrier exclusively expressed in brown adipose tissue
128. Uncoupling protein-2: A novel gene linked to obesity and hyperinsulinemia
129. The autonomic nervous system, adipose tissue plasticity, and energy balance
130. Uncoupling protein-3: A new member of the mitochondrial carrier family with tissue-specific expression
131. Genetically lean mice result from targeted disruption of the RII beta subunit of protein kinase A
132. Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean
133. Neuropeptide regulation of appetite and weight
134. Candidate gene polymorphisms in eating disorders
135. Overview of adrenergic anorectic agents
136. The antidiabetic beta 3-adrenoceptor agonist BRL 26830A works by release of endogenous insulin
137. Food intake of lean and obese Zucker rats following ventricular infusions of adrenergic agonists
138. Targeted disruption of the beta 3-adrenergic receptor gene
139. Effect of CL-316,243, a thermogenic beta 3-agonist, on energy balance and brown and white adipose tissues in rats
140. Beta3-adrenergic receptors on white and brown adipocytes mediate beta3-selective agonist-induced effects on energy expenditure, insulin secretion, and food intake: A study using transgenic and gene knockout mice
141. Role of the beta(3)-adrenergic receptor and/or a putative beta(4)-adrenergic receptor on the expression of uncoupling proteins and peroxisome proliferator-activated receptor-gamma coactivator-1
142. Beta 3-adrenergic agonist up-regulates uncoupling proteins 2 and 3 in skeletal muscle of the mouse
143. Mechanism of amelioration of insulin resistance by beta3-adrenoceptor agonist AJ-9677 in the KK-Ay/Ta diabetic obese mouse model
144. Effects of beta-adrenergic receptor stimulation and blockade on substrate metabolism during submaximal exercise
145. Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity
146. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene
147. Association of a polymorphism in the beta 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns
148. Additive effects of the mutations in the beta3-adrenergic receptor and uncoupling protein-1 genes on weight loss and weight maintenance in Finnish women
149. Leptin-induced increase in sympathetic nervous and cardiovascular tone is mediated by proopiomelanocortin (POMC) products
150. Human leptin deficiency caused by a missense mutation: Multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects
151. Enhanced leptin transport across the blood-brain barrier by alphal-adrenergic agents
152. Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells
153. Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean
154. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance
155. The expression of tumor necrosis factor in human adipose tissue: Regulation by obesity, weight loss, and relationship to lipoprotein lipase
156. The expression of TNF alpha by human muscle: Relationship to insulin resistance
157. Journey from cachexia to obesity by TNF
158. Tumour necrosis factor, a key role in obesity?
159. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight
160. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: Effects of confounding factors and diagnosis
161. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels
162. Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine
163. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine
164. Tumor necrosis factor-alpha inhibits leptin production in subcutaneous and omental adipocytes from morbidly obese humans
165. Variations in plasma soluble tumour necrosis factor receptors after diet-induced weight loss in obesity
166. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance
167. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function
168. Targeted disruption of the tumor necrosis factor-alpha gene: Metabolic consequences in obese and nonobese mice
169. Tumor necrosis factor alpha mediates apoptosis of brown adipocytes and defective brown adipocyte function in obesity
170. Endotoxin-induced alteration in the expression of leptin and beta3-adrenergic receptor in adipose tissue
171. Nitric oxide-dependent downregulation of adipocyte UCP-2 expression by tumor necrosis factoralpha
172. Uncoupling protein-2 gene: Reduced mRNA expression in intraperitoneal adipose tissue of obese humans
173. Tumor necrosis factor-alpha stimulates cell proliferation in adipose tissue-derived stromal-vascular cell culture: Promotion of adipose tissue expansion by paracrine growth factors
174. Linkage between obesity and a marker near the tumor necrosis factor-alpha locus in Pima Indians
175. Role of tumor necrosis factor-alpha gene locus in obesity and obesity-associated hypertension in French Canadians
176. The TNF-alpha gene Nco I polymorphism influences the relationship among insulin resistance, percent body fat, and increased serum leptin levels
177. Polymorphisms of the tumour necrosis factor-alpha gene, coronary heart disease and obesity
178. Excessive fat accumulation is associated with the TNF alpha-308 G/A promoter polymorphism in women but not in men
179. Tumor necrosis factor-alpha-308 G/A polymorphism in obese Caucasians
180. The role of tumor necrosis factor-alpha in the pathogenesis of anorexia and bulimia nervosa, cancer cachexia and obesity
181. Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD)
182. Polymorphism of the human TNF-alpha promoter: Random variation or functional diversity?
183. Human genomics and obesity: Finding appropriate drug targets
184. Association versus linkage studies in psychosis genetics
185. The human obesity gene map: The 1998 update
186. Dietary fat intake does affect obesity!
187. Genetic dissection of complex traits
188. Cutting a Gordian knot in the linkage analysis of complex human traits
189. Candidate genes in psychiatry: An epidemiological perspective
190. Benefits and pitfalls encountered in psychiatric genetic association studies
191. Pharmacogenetic prediction of clozapine response
192. 2A receptor and response to clozapine
193. 6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia